Literature DB >> 9663476

Changes in biochemical markers of joint tissue metabolism in a randomized controlled trial of glucocorticoid in early rheumatoid arthritis.

M Sharif1, C Salisbury, D J Taylor, J R Kirwan.   

Abstract

OBJECTIVE: To determine the effects of low-dose prednisolone on joint tissue metabolism in early rheumatoid arthritis (RA).
METHODS: In addition to a range of biochemical markers of cartilage, bone and synovial tissue turnover, levels of pro-matrix metalloproteinase 3 (pro-MMP-3), pro-MMP-1, and cytidine deaminase (CD) were measured in serum from 79 of 128 patients with early RA who took part in the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study. Serum concentrations of joint tissue metabolites on treatment and off treatment were compared using Student's t-test.
RESULTS: Levels of the keratan sulfate epitope, 5D4, and glycosaminoglycan (GAG) were similar on and off treatment. However, the levels of synovium-derived markers, hyaluronate (HA) and N-propeptide of type III procollagen (PIIINP), were reduced by 23.9% (P < 0.01) and 25.2% (P < 0.001), respectively, during treatment with prednisolone. Serum osteocalcin (OC) was reduced by 25.8% (P < 0.001), while the levels of CD and pro-MMP-3 increased by 31.2% (P < 0.01) and 53.7% (P < 0.001) during prednisolone treatment compared with the off-treatment period.
CONCLUSION: Low-dose prednisolone had no significant effect on markers of cartilage turnover (GAG, 5D4) in early RA, suggesting that early erosions do not involve cartilage surfaces. The reduction in the markers of bone turnover (OC) and synovial tissue turnover (HA and PIIINP) support the general view that prednisolone reduces synovitis and suppresses bone turnover.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9663476     DOI: 10.1002/1529-0131(199807)41:7<1203::AID-ART9>3.0.CO;2-2

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  8 in total

1.  Markers of joint destruction: principles, problems, and potential.

Authors:  S A Young-Min; T E Cawston; I D Griffiths
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

2.  Influence of intraarticular corticosteroid administration on serum cytokines in rheumatoid arthritis.

Authors:  Philip Alex; Peter Szodoray; Eugene Arthur; Larry Willis; Robert Hynd; Don Flinn; Michael Centola
Journal:  Clin Rheumatol       Date:  2006-10-05       Impact factor: 2.980

3.  Caution is needed when interpreting changes of matrix metalloproteinase-3 in patients with rheumatoid arthritis.

Authors:  Takao Nagashima; Seiji Minota
Journal:  Rheumatol Int       Date:  2013-07-26       Impact factor: 2.631

4.  Updating the OMERACT filter: implications for imaging and soluble biomarkers.

Authors:  Maria-Antonietta D'Agostino; Maarten Boers; John Kirwan; Désirée van der Heijde; Mikkel Østergaard; Georg Schett; Robert B Landewé; Walter P Maksymowych; Esperanza Naredo; Maxime Dougados; Annamaria Iagnocco; Clifton O Bingham; Peter M Brooks; Dorcas E Beaton; Frederique Gandjbakhch; Laure Gossec; Francis Guillemin; Sarah E Hewlett; Margreet Kloppenburg; Lyn March; Philip J Mease; Ingrid Moller; Lee S Simon; Jasvinder A Singh; Vibeke Strand; Richard J Wakefield; George A Wells; Peter Tugwell; Philip G Conaghan
Journal:  J Rheumatol       Date:  2014-03-01       Impact factor: 4.666

5.  Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment.

Authors:  C Ribbens; M Martin y Porras; N Franchimont; M-J Kaiser; J-M Jaspar; P Damas; F A Houssiau; M G Malaise
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

6.  Changes of cartilage and bone markers after intra-articular glucocorticoid treatment with and without postinjection rest in patients with rheumatoid arthritis.

Authors:  T Weitoft; A Larsson; T Saxne; L Rönnblom
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

Review 7.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

8.  Usefulness of tissue inhibitor of metalloproteinase 1 as a predictor of sustained remission in patients with antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Jun Ishizaki; Ayako Takemori; Kenta Horie; Daisuke Hiraoka; Koichiro Suemori; Takuya Matsumoto; Ken-Ei Sada; Koichi Amano; Masayoshi Harigai; Yoshihiro Arimura; Hirofumi Makino; Katsuto Takenaka; Nobuaki Takemori; Hitoshi Hasegawa
Journal:  Arthritis Res Ther       Date:  2021-03-20       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.